

## Index

- A1C, S5, S6, S7, S12, S20, S24, S25, S26, S27, S56, S57, S59  
 advantages of, S22  
 age and, S23  
 alternatives to, **S112**  
 cardiovascular disease and, S116–S117  
 by CGM, **S112, S113–S114**  
 confirming diagnosis with, S22  
 correlation with BGM, S112  
 diabetes distress and, S94  
 equivalent eAG levels, S112  
 for diabetes screening and diagnosis, S21–S22  
 glycemic assessment by, S7, **S112**  
 hemoglobinopathies and, S22  
 in children, **S30, S263–S264, S268, S269, S270–S271**  
 in cystic fibrosis-related disease, S31  
 in gestational diabetes mellitus, S34–S35  
 in hyperglycemia, S64  
 in people with HIV, **S30**  
 in preclinical type 1 diabetes, S43  
 in staging type 1 diabetes, S24, S25  
 limitations, S7, S112  
 microvascular complications and, **S115–S116**  
 in prediabetes, S27–S28, S43–S44  
 in pregnancy, S22, **S285–S286**  
 other conditions affecting, S22  
 periodontal disease and, S69  
 point-of-care assays S21, S22, S112  
 race/ethnicity and, **S22, S79**  
 recommendations, **S21–S22**  
 serum glycosylated protein assays versus, **S112**  
 setting and modifying goals for, **S113–S118**  
 sleep and, S97
- AABCC approach, S23  
 acarbose, S68, S154, S174  
 access to care, S14  
 access, to insulin, S308  
 ACCORD study, S60, S64, S116, S117, S118, S181, S182, S183, S192, S222, S236, S246  
 ACE inhibitors, S9, S56, S184, S185, S186, S195, S202, **S205, S220, S222, S223–S224, S266, S271, S283, S289**  
 acellular matrix tissues, S40  
 acute kidney injury, S151–S152, S181, S183, **S186, S222**  
 ADA consensus reports, S4, S9, S32, S54, S80, S88, S113, S147, S160, S164, S165, S179, S197, S202, S245  
 ADA evidence-grading system, S3  
 ADA Professional Practice Committee, S1, S2, S309  
 ADA scientific reviews, S4  
 ADA statements, S4  
 ADAG study, S112  
 Addison disease, S24, S59, S265  
 adolescents. *see* children and adolescents.  
 adrenal insufficiency, primary, S59, S265  
 adult-onset diabetes. *see* Type 2 diabetes.  
 ADVANCE trial, S64, S116, S117, S118, S181, S182, S183  
 advocacy statements, **S307–S308**  
 care of young children with diabetes in the childcare setting, S307  
 diabetes and driving, S308  
 diabetes and employment, S308  
 diabetes care in the school setting, S308  
 insulin access and affordability, S308  
 affordability, of insulin, S308  
 Affordable Care Act, S14, S274  
 African Americans, S15, S22, S23, S26, S27, S28, S29, S87, S221  
 age  
 aspirin use and, S193–S194  
 effect on A1C, **S23**  
 in diabetes diagnosis and classification, S23–S29  
 risk factor for diabetes, S29, **S30**  
 statin treatment and, S188  
 agricultural workers, migrant, S15–S16  
 AIM-HIGH trial, S192  
 albiglutide, S204, S205, S206  
 albuminuria, S9, S85, S87, S90, S119, S165, S180, S182, S185, S186, S193, S195, S199, S205, S207, S209–S210, S219, S220, **S221, S222–S227, S265, S267, S273**  
 alcohol intake, S6, S55, S59, S65, S81, **S86, S98, S119, S154, S184, S191, S235, S237, S283**  
 algorithms  
 for diabetic retinopathy screening, S232  
 insulin dosing, S126, S133, S135, S222, S246, S288, S296  
 to predict hypoglycemia, S300  
 alirocumab, S188, S189, S190  
 alogliptin, S172, S196, S197, S206, S299  
 alpha-glucosidase inhibitors, S46, S148, S172  
 alpha-lipoic acid, S237  
 ambulatory glucose profile (AGP), S113, S114, S115, S131, S286  
 amputation, foot, S9, S64, S202, S203, S234, S237, S238, S239, S240  
 analogs. *see* insulin analogs.  
 angiotensin receptor blockers (ARBs), S9, S56, S184, S222, S266, S267, S271, S284, S289  
 anti-VEGF agents, **S233–S234**  
 antiplatelet agents, **S192–S194, S247**  
 antipsychotics, S28, S96, S148  
 antiretroviral therapies, S27, S30  
 anxiety disorders, S15, S56, S91, S92, S93, **S94, S134, S154, S234, S263**  
 ARRIVE trial, S193  
 artificial intelligence algorithms, for diabetic retinopathy, S232  
 ASCEND trial, S85, S193  
 Asian Americans, S26, S27, S28, S29, S45, S149, S153  
 aspart, S170, S173, S250  
 aspirin therapy, S10, **S192–S194, S233, S248, S289**  
 ASPREE trial, S193  
 atenolol, S237, S289  
 atherosclerotic cardiovascular disease (ASCVD), S57, S165, S166, S168, S169, **S179–S218**  
 atorvastatin, S188, S190  
 autoimmune diseases, S23, S26, **S59, S265–S266, S289**  
 autoimmune type 1 diabetes, S23, S24, S32, S268  
 autologous blood products, S240  
 automated insulin delivery (AID) systems, S7, S8, S83, S84, S97, S116, S119, S120, S126, S127, **S133–S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297**  
 autonomic neuropathy, diabetic, S59, S89, **S90, S181, S234, S235, S301**  
 balloons, implanted gastric, S149  
 bariatric surgery. *see* metabolic surgery.  
 basal insulin, S10, S119, **S129, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, S170, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302**  
 bedtime dosing  
 of antihypertensives, **S186**  
 of insulin, S155, S162, S163, S248  
 behavioral therapy, **S147–S148**  
 behaviors, changes in, S6, **S77–S110**  
 cost considerations for medication-taking, S6, **S13–S14**  
 diabetes self-management education and support, **S77–S80**  
 for diabetes prevention, **S44–S46**  
 medical nutrition therapy, **S80–S86**  
 physical activity, **S86–S90**  
 in gestational diabetes, **S287**  
 psychosocial care, **S91–S98**  
 smoking cessation, **S90–S91**  
 supporting positive health behaviors, **S91**  
 well-being and, S13  
 bempedoic acid, S8, S187, **S191**  
 beta-carotene, S81, S85  
 beta-cell replacement therapy, S161, S164  
 biguanides, S172  
 bioengineered allogeneic cellular therapies, S240  
 bladder dysfunction, S235, S284  
 Blood Glucose Awareness Training, S121  
 blood glucose monitoring (BGM), S53, **S127–S129, S160, S163**  
 in hospitalized patients, **S297**  
 continuous glucose monitoring, **S129–S132**  
 correlation with A1C, **S112**  
 devices for, **S126–S127**  
 during pregnancy, S284, **S285**  
 in children and adolescents, S264, S269, S271  
 in intensive insulin regimens, **S129**  
 in older adults, S246, S251  
 in people on basal insulin, oral agents, or noninsulin injectables, **S129**  
 in schools, **S127**  
 inaccuracy of, **S129**  
 interfering substances, S129  
 meter standards, **S128**  
 optimizing device use, **S128–S129**  
 surveillance of, S128  
 blood pressure control. *see also* hypertension, S180–S186, S205, S219, S222  
 body mass index (BMI), S7, S10, S23, S25, S26, S31, S45, S46, S47, S56, S59, S87, S88, S146, S149, S223,  
 COVID-19 mortality and, S62  
 effects of metformin use in pregnancy on, S287, S288, S290  
 for metabolic surgery, S150, S153, S271  
 in obese patients, S146–S147, S148  
 in screening asymptomatic adults, S27  
 in screening asymptomatic children, S27, S268  
 postpartum, S290  
 bone fracture risk, S59–S62, S68  
 bone-strengthening activities, S86, S87, S261, S270

- breastfeeding, *see* lactation.  
bromocriptine, S148, S172
- calcium channel blockers, S186, S224  
canagliflozin, S62, S169, S172, S197, S200, S203, S205, S206, S207, S224, S225  
cancer, risk in diabetics, **S62**  
cannabis, S6, **S90–S91**,  
CANVAS study, S62, S197, S200–S201, S203, S207, S224, S226  
CANVAS-R study, S203  
capsaicin, topical, **S236**  
carbamazepine, S236  
carbohydrate intake, S26, S81, S84, S86, S158, S162–S163, S261–S262, S286  
cardiac autonomic neuropathy, diabetic, **S235**  
cardiac function testing, **S272–S273**  
cardiovascular disease, S2, S7, **S179–S218**  
antiplatelet agents, **S192–S194**  
cardiac testing, **S195–S196**  
heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227  
    hypertension/blood pressure control, **S180–S186**  
    lifestyle and pharmacologic interventions, **S202–S205**  
    lipid management, **S186–S187**  
    prevention of, **S47**  
    risk calculator, **S180**  
    screening, **S194–S195**  
    statin treatment, **S187–S192**  
    treatment, **S196**  
cardiovascular risk, S14, S16, S27, S33, S47, S54, S60, S63, S65, S67, S68, S85, S87, S88, S116–S117, S146, S153, S164–S165, S168, S179, **S180–S184**, S187, S188, S190, S191, S193, S194, S195–S197, S202, S204, S205, S206, S208, S210, S219–S220, S222, S223, S226, S235, S236, S245, S247, S248, S259, S261, **S266–S267**,  
care delivery systems, S5  
    access to care and quality improvement, S14  
    behaviors and well-being, S13  
    care teams, S13  
    chronic care model, S12  
    medication cost considerations, S13–S14  
    six core elements, S12  
    system-level improvement strategies, S12–S13  
    telehealth, S13  
care teams, **S13**, S91, S92, S93, S95, S127, S136, S273  
CARMELINA trial, S196, S206  
CAROLINA trial, S196, S202  
celiac disease, S24, S59, S61, S259, **S265–S266**  
CHAP trial, S184, S289  
Charcot neuropathy, S9, S88, S90, S237, S238, S239  
childcare, S10, S120, **S262**, S307  
children and adolescents, S7, S9, **S258–S281**  
    A1C in, **S30**, S263–S264, S268, S269, S270–S271  
    asymptomatic, risk-based screening in, S27  
    cystic fibrosis-related diabetes in, S6, S21, S23, S31, S111, S135, S258, S268, S284  
    diabetes care in childcare settings, S10, S120, **S262**, S307  
    diabetes care in school setting, **S127**, S261, **S262**, S263, S268, S308  
    insulin pumps in, S7, S263, S270  
    maturity-onset diabetes of the young (MODY), S22, **S32–S33**  
    monogenic diabetes syndromes, **S32–S34**  
    neonatal diabetes, S22, **S32**, **S33**  
    physical activity in, S45, S86, **S87**  
    screening for type 1 risk, S26, **S267**  
    screening for prediabetes and type 2, S27, **S30**, **S268**  
    substance abuse, S273  
    transition from pediatric to adult care, **S273–S274**  
    type 1 diabetes in, S14, S23, S24, S46, **S261–S268**  
    type 2 diabetes in, **S268–S273**  
CHIPS trial, S184, S289  
cholesterol lowering therapy, S9, S56, S187, S190, S191  
chronic care model, S11 **S12**, S52, S269  
chronic kidney disease, diabetic, S8, S9, S32, S53, S54, S56, S57, S66, S87, S117, S119, S120, S161, S164, S165, S166, S180, S195, S199, **S209–S210**, **S219–S230**, S244, S248, S249, S252  
    acute kidney injury, S151–S152, S181, S183, **S186**, **S222**  
    assessing albuminuria and GFR, **S221**  
    diagnosis, **S221**  
    epidemiology, **S221**  
    interventions for, **S223–S227**  
    referral to nephrologist, **S227**  
    risk of progression, S223, S224, S226  
    screening recommendations, **S219**  
    staging, S221  
    surveillance, **S222–S223**  
    treatment recommendations, **S219–S221**  
chrononutrition, S83  
classification, S5, **S22–S23**  
clonidine, S237, S289  
clopidogrel, S193, S194  
closed-loop systems, S135  
    do-it-yourself, **S135**  
    hybrid, S7, S8, S135, S159, S162, S246, S297  
coaching, online, S78, S136  
cognitive capacity/impairment, S96–S97  
colesevelam, S148, S172  
collaborative care, **S52–S54**, S94, S95, S197–S198  
collagen vascular diseases, S59  
combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252  
community health workers, S14, S16, S45, S52, S79, S91, S169  
community screening, **S30**  
community support, S5, S14, **S16**, S97, S262, S273  
comorbidities, S6, S9, S12, S23, S32, **S43**, S47, **S52–S76**  
    assessment of, **S59–S69**  
    autoimmune diseases, S59  
    bone health and fractures, S59–S62  
    cancer, **S62**  
    cognitive impairment/dementia, **S62**  
    COVID-19, **S62–S64**  
    disability, **S64**  
    hepatitis C, **S64**  
    hyperglycemia, **S64**  
    hypoglycemia, **S64–S65**  
    low testosterone in men, **S65**  
    nonalcoholic fatty liver disease, **S65–S68**  
    obstructive sleep apnea, **S68–S69**  
    pancreatitis, **S69**  
    periodontal disease, **S69**  
    prevention or delay of, S6, **S43–S51**  
    sensory impairment, S77  
COMPASS trial, S194  
computerized prescriber order entry (CPOE), S298  
CONCEPTT study, S285, S286  
connected insulin pens, S126, S127, S133, S161, S263  
continuous glucose monitoring (CGM), S7, S8, S9, S10, S21, S31, S53, S55, S56, S78, S83, S84, S95, S111, **S113–S117**, S126–S127, S128, S159, S162–S163, S166  
    ambulatory glucose profile in, S113, S114, S115, S131, S286  
    assessment of glycemic status with, **S113**  
    benefits of, S130  
    devices for, **S129–S130**  
    in hospitalized patients, S136, **S297–S298**, **S299–S300**  
    in hypoglycemia prevention, S118, S121  
    in older adults, **S246**, S253  
    in pediatric type 1 diabetes, S263–S265  
    in pediatric type 2 diabetes, S269–S271  
    in pregnancy, S131–S132, S284, **S286**  
    initiation of device use, S127  
    interfering substances, S132  
    intermittently scanned devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269  
    real-time, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297  
    side effects, S132  
continuous subcutaneous insulin infusion (CSII), S126, S127, S129–S130, S133, S135, S159, S160, S161  
contraception, S149, S152, S259, S260, S263, S266, S267, S271, S272, S273, S282–S283, S284, S289, **S291**  
coronary artery disease, S88, S184, S185, S186, S194, S197, S202, S205  
cost considerations, **S13–S14**, S149–S153, S159–S160, S165, S169, S170, S173  
counterfeit test strips, S128  
COVID-19, S5, S6, S26, S28, **S54–S56**, **S62–S64**, S80, S297  
COVID-19 vaccines, S56, S58, S64–S65, S285  
CREDENCE study, S62, S200–S201, S203, S207, S225, S226  
cystatin C, S221  
cystic fibrosis-related diabetes, S6, S21, S23, S31, S111, S135, S258, S268, S284  
Da Qing Diabetes Prevention Outcome Study, S44, S47, S48  
DAPA-CKD study, S200–S201, S203, S225, S226  
DAPA-HF study, S200–S201, S203, S206, S207  
dapagliflozin, S62, S63, S169, S172, S200–S201, S203, S204, S206, S207, S225, S226  
DARE-19 study, S63  
DASH diet, S45, S82, S184, S186  
DECLARE-TIMI 58 study, S200–S201, S203, S207, S226  
degludec, S159, S170, S172, S174, S250, S298  
delay, of symptomatic type 1 diabetes, S48  
delay, of type 2 diabetes, S5–S6, **S43–S51**  
    lifestyle behavior change, **S44–S46**  
    person-centered care goals, **S47–S48**  
    pharmacologic interventions, **S46–S47**  
    recommendations, S43, S44, S46, S4, S487  
    of vascular disease and mortality, **S47**  
DELIVER study, S200–S201, S204, S207  
dementia, in diabetics, S62, S64, S65, S69, S96, S119, S192, S245–S246

- demographics, of diabetes care, S12–S14
- dental practices, screening in, S30, S55, S57
- depression, S7, S15, S56, S88, S91, S92, S93, S94, **S95**, S97, S134, S150, S154, S234, S236, S244, S245, S248, S251, S263, S273
- detemir, S162, S170, S173, S250
- devices. *see* technology.
- Diabetes Control and Complications Trial (DCCT), S21, S22, S69, S116, S159, S264, S267
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S69, S117, S120, S246
- diabetes distress, S6, S9, S12, S15, S56, S91, S92, **S93–S94**, S130, S159, S262, S263, S273, S303
- diabetes medical management plan (DMMP), for students, S127
- Diabetes Prevention Impact Tool Kit, S45
- Diabetes Prevention Program (DPP), S27, S28, **S44**, S45, S46, S48, S86, S136
- Diabetes Prevention Program Outcomes Study (DPPOS), S28, S44, S46, S48, S47, S86, S168
- Diabetes Prevention Recognition Program (DPRP), S46
- diabetes self-management education and support (DSMES), S6, S13, S16, S54, **S77–S80**, S82, S94, S172
- diabetes technology. *see* technology, diabetes.
- diabetic ketoacidosis, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**
- diabetic kidney disease. *see also* chronic kidney disease.
- dietary protein and, S75
- diagnosis, S221
- physical activity and, **S90**
- finerenone in, S202, **S206**, **S209–S210**, S225, S226–S227
- glucose-lowering medications for, S224–S227
- multiple drug therapy, S186
- prevention, S222
- screening for complications of, S223
- Diabetic Retinopathy Study (DRS), S234
- diagnosis, S5, S6, **S20–S37**
- confirmation of, S22
- criteria for, S21
- cystic fibrosis-related, S22, **S31**
- diabetic kidney disease, S221
- diagnostic tests, S20–S22
- gestational diabetes, S34–S37
- maturity onset diabetes of the young (MODY), S32, S33
- monogenic diabetes syndromes, **S32–S34**
- neonatal diabetes, S32
- posttransplantation diabetes mellitus, **S31–S32**
- prediabetes and type 2, **S26–S31**
- type 1, **S24–S26**,
- diagnostic tests, S20–S22
- A1C use as, **S21–S22**
- confirmation of, S22
- criteria for, S21
- fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171
- oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
- plasma glucose test, 2-h, S20, **S21**, S23, S24, S26, S27, S30, S33, S35
- diet, *see* Medical nutrition therapy.
- Dietary Reference Intakes, S287
- DIAMOND trial, S246
- digital health technology, **S136**
- dipeptidyl peptidase 4 (DPP4) inhibitors, S62, S68, S148, S166, S167, S168, S172, S196, S202, S250, S252, S298
- disordered eating behavior, S56, S82, S84, S91, S92, S93, **S95–S96**, S261, S262, S263, S273, do-it-yourself systems, **S135**, S159
- domperidone, S237
- Dose Adjusted for Normal Eating (DAFNE), S121
- DRCR Retina Network, S233
- driving, and diabetes, S308
- droxidopa, S237
- dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP), S8, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252
- dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S8, S62, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252
- dulaglutide, S165, S169, S172, S198, S204, S205, S206, S232,
- duloxetine, S236
- dyslipidemia, S12, S13, S27, S28, S47, S56, S66, S87, S96, S97, S148, S179, S180, S191, S192, S193, S202, S231, S234, S236, S248, S259–S260, **S266–S267**, S270, S272
- e-cigarettes, S6, **S90–S91**
- eating disorders, S82, S95, S263
- eating patterns, S6, S44–S45, S53, S55, S68, S80, S81, **S82**, S84, S85, S93, S95, S96, S269,
- education, *see also* diabetes self-management education and support (DSMES).
- on device use, **S127**
- patient, S7, S13, S16, S120, S121, S239, S264
- preconception, S262, S263, S273, **S282–S283**, S284
- staff, S10, S128, S253, S297
- electrical stimulation, gastric, S237, S240
- ELIXA trial, S198–S199, S204
- EMPA-REG OUTCOME trial, S200, S201, S203, S206–S207, S224
- empagliflozin, S10, S62, S169, S172, S200–S201, S203–S204, S205, S206, S207, S224, S226, S269, S270, S271
- EMPEROR-Preserved trial, S200–S201, S203, S207, S226
- EMPEROR-Reduced trial, S200–S201, S203, S207, S226
- employment, diabetes and, S308
- enalapril, S205, S237
- end-of-life care, S248, **S254**
- enteral/parenteral feedings, S298, **S300–S301**
- erectile dysfunction, S65, S235, **S237**
- ertugliflozin, S62, S172, S200, S204, S205, S299
- erythromycin, S237
- erythropoietin therapy, A1C and, S22, S247
- estimated average glucose (eAG), S112
- ETDRS study, S233, S234
- ethnicity, S2, S12, S15, S23, S25, S27, S28, S30, S34, S45, S62, S63, S64, S79, S112, S262, S268
- evidence-grading system, S3
- evolocumab, S188, S189, S190–S191
- EXAMINE trial, S196, S197, S206
- exenatide, S172, S198, S205, S206
- exercise. *see* physical activity.
- exocrine pancreas diseases, S6, S30, S69
- EXSCEL trial, S198–S199, S205,
- eye exam, S55, S57, S232, S267, S272, S283
- ezetimibe, statins and, S187, **S189**, S190, S192
- family history, S23, S25, S26, S27, S28, S32, S34, S55, S59, S62, S95, S180, S193, S268, S271
- farmworkers, migrant and seasonal, S15–16
- fasting, S6, S10, S20, S21, S23, S25, S35, S36, **S83**, S119, S127,
- fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171
- fats, dietary, S6, S81, **S85**, S154, S266, S272, S284, S285, S287,
- FDA standards, for glucose meters, S128
- fear, of hypoglycemia, S56, S91, S92, S93, S94, S119, S121, S159, S244, S263
- fenofibrate, S192, S234
- fibrate, S260, S272
- plus statin therapy, **S192**
- fibrosis-4 index, S65, S66, S67,
- FIDELIO-DKD trial, S206, S209, S226, S227
- FIGARO-DKD trial, S206, S209, S227
- finerenone, S195, S202, **S206**, **S209–S210**, S225, S226–S227
- fish skin graft, S240
- FLOW trial, S266
- fluvastatin, S188
- food insecurity, S15
- foot care, S9, **S237–S241**, S268
- footwear, S90, S237, S239
- FOURIER trial, S189
- fracture risk, S6, S59, S60–S62, S68,
- gastrectomy, vertical sleeve, S153
- gastric aspiration therapy, S149
- gastric bypass, Roux-en-Y gastric, S153
- gastric electrical stimulation, S237
- gastrointestinal neuropathies, **S235**
- gastroparesis, S8, S235, **S237**, S252
- gemfibrozil, S192
- genetic testing, S25, S32–S33, S66
- genitourinary disturbances, **S235**
- gestational diabetes mellitus (GDM), S10, S23, S27, **S34–S37**, S45, S46, S47, S81, S88, S95, S97, S132, S232–S233, **S286–S288**
- definition, S34
- diagnosis, S35–S36
- insulin, **S288**
- lifestyle and behavioral management, S287
- management of, **S286–S288**
- medical nutrition therapy, S287
- metformin, S287
- one-step strategy, S35
- pharmacologic therapy, S287–S288
- physical activity, S287
- postpartum care, S290
- screening, S35–S36
- sulfonylureas, S287
- two-step strategy, S37
- glargine, S159, S162, S169, S170, S172, S173, S174, S250, S298
- glimepiride, S169, S172, S196, S202
- glipizide, S172, S252
- glomerular filtration rate, S8, S9, S56, S61, S85, S119, S161, S165, S166, S167, S168, S185, S186, S195, S196, S199, S201, S219, S220, **S221**, S223, S225, S250, S267, S271
- glucagon, S7, S8, S31, S118, **S120–S121**, S158, S169, S170, S208, S224, S225, S231,
- glucagon-like peptide 1 receptor agonists (GLP-1 RA), S8, S28, S62, S67, S68, S116, S148, S151, S152, S160, S164, S166, S167, S171, S172, S173, S195, S196, S199, S204, S209, S220, S245, S249, S269, S270, S299
- glucocorticoid therapy, **S301**

- glucose meters, S7, S119, S127, S128–S129  
 counterfeit strips, S128  
 inaccuracy, S129  
 interfering substances, S129  
 optimizing use of, S128  
 oxygen, S129  
 standards, S128  
 temperature, S129
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S22, S112,
- glucose-lowering therapy, S33, S148, S165
- glulisine, S173, S250,
- glyburide, S10, S172, S252, S286, S287
- glycemic goals, S7, S8, S9, S10, **S111–S125**  
 assessment of glycemic status, **S111–S113**  
 cardiovascular disease outcome with, **S116–S117**  
 continuous glucose monitoring, **S113–S114**  
 for nonpregnant adults, **S116**  
 in diabetic kidney disease, **S223**  
 in hospitalized patients, **S296–S297**  
 in pregnancy, **S284–S285**  
 hypoglycemia, **S118–S121**  
 intercurrent illness, **S121**  
 in older adults, S246–S249  
 in pediatric type 1 diabetes, **S263–S265**  
 in pediatric type 2 diabetes, **S269**  
 setting and modifying A1C goals, S117–S118
- glycemic treatment, S7, **S158–S178**  
 for adults with type 1 diabetes, S158–S164  
 for adults with type 2 diabetes, S164–S174
- growth factors, S240
- guanfacine, S237
- health literacy, S14, S15, **S16**, S80, S119, S247, S262, S273
- health numeracy, S13, S14, S15, **S16**, S53, S79, S80, S83, S84, S162, S247, S261
- health promotion, S11–S19
- hearing impairment, S69
- heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227
- hemodialysis, A1C and, S22, S247
- hemoglobinopathies, A1C and, S35, S44, S55, S268
- hepatitis B, S222, S284
- hepatitis B vaccines, **S56**, S58, S284
- hepatitis C infection, **S64**, S284
- hepatitis, autoimmune, S24, S265
- high-intensity interval training, S6, **S88**
- Hispanic/Latino population, S15, S22, S27, S28, S79, S87
- homelessness, S5, S14, **S15**, S55, S119, S262, S273
- hospital care, S10, **S295–S306**  
 care delivery standards, **S295–S296**  
 continuous glucose monitoring, **S297**  
 diabetes care specialists in, S296  
 diabetic ketoacidosis, **S301–S302**  
 enteral/parenteral feedings, **S300**  
 glucocorticoid therapy, **S301**  
 glucose-lowering treatment in, **S298–S299**  
 glucose monitoring, **S297–S298**  
 glycemic goals in, **S296–S297**  
 hyperosmolar hyperglycemic state, **S301–S302**  
 hypoglycemia, **S299–S300**  
 insulin therapy, S298–S299
- medical nutrition therapy in, **S301**  
 medication reconciliation, S302  
 noninsulin therapies, S299  
 perioperative care, S301  
 preventing admissions and readmissions, **S303**  
 self-management in, **S300**  
 standards for special situations, **S300–S301**  
 structured discharge communication, S302  
 transition to ambulatory setting, S295, **S302–S303**
- HOT trial, S182, S183
- housing insecurity, S5, **S15**
- HPS2-THRIVE trial, S192
- human immunodeficiency virus (HIV), S22, S23, S26–S27, **S30**, S235, S284
- human regular insulin, S170, S173, S301, S302
- hybrid closed-loop systems. *see* automated insulin delivery systems.
- hydrogel, oral, S149
- hyperbaric oxygen therapy, S239, S240
- hyperglycemia, S10, S15, S21, S22, S23, S24, S25, S26, S28, S30, S31–S32, S34, S35, S47, S63, **S64**, S67, S68, S69, S83, S86, S88, S95, S97, S111, S113, S115, S121, S127, S128, S131–S132, S135, S146, S153, S165, S168, S170, S171, S221, S231, S232, S246, S247, S248, S251, S253, S254, S261–S262, S264, S269, S272, S282, S284, S285, S286, S290, S295, S296, S297, S298–S299, S301–S302
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S36, S285
- hyperosmolar hyperglycemic state, S10, S64, S121, S247, S269, S270, S298, S301–S302
- hypertension, S9, S12, S13, S27, S28, S45, S47, S57, S65, S66, S85, S87, S88, S97, S116, S146, S148, S159, S179, **S180–S186**, S193, S199, S202, S205, S221, S222, S223, S224, S225, S227, S231, S236, S244, S247, S248, S250, S254, S259, S260, S266, S270, **S271**, S272, S282, S284, S286, S288, S289
- hypertriglyceridemia, S85, S159, S168, S191
- hypoglycemia, **S64–S65**, **S118–S125**, S129, S130–S132, S134–S135, S136, S150–S154, S158–S165, S168–S169, S170, S174, S203, S208, S210, S223, S234, S235, S244, **S245–S246**, S249–S250, S251, S252, **S253–S254**, S261–S265, S269, S282, S282–S288, S291, S295, S296–S297, S298, **S299–S300**, S301–S302
- hypogonadism, S65, S237
- hypokalemia, S186, S220, S222
- icosapent ethyl, S85, S191, S225
- idiopathic type 1 diabetes, **S27**
- illness, intercurrent, glycemic targets in, **S121**, S129
- immune checkpoint inhibitors, S23, S26
- immune-mediated diabetes, **S24**
- immunizations, **S54–S59**
- impaired fasting glucose (IFG), S21, S24, S27, S28, S43, S48
- impaired glucose tolerance (IGT), S21, S24, S27, S28, S36, S43, S47, S48
- inlisiran, S9, S187, S189–S191
- incretin-based therapies, S31, S69, **S252**
- Indian Diabetes Prevention Program (IDPP-1), S46
- infections, S5, S26, S31–S32, S54–S59, S63, S64, S90, S134, S235, S239, S251, S252, S301
- influenza vaccines, **S56–S57**, S58
- inhaled insulin, S8, S133, S158, S160, S173
- injection techniques, S133, S161, **S160–S161**
- inpatient care. *see* hospital care.
- insulin analogs, S8, S134, S158, S159, S162, S169, S170, S174, S252, S264, S298, S302
- insulin delivery, S7, S8, S57, S83, **S132–S136**  
 automated systems, S7, S8, S83, S84–S85, S97, S116, S119, S120, S126, S127, S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297  
 do-it-yourself closed-loop systems, **S135**, S159  
 injection techniques, S133, S161, **S160–S161**  
 IV, transitioning to SC, **S298–S299**  
 pens and syringes, **S132–S133**  
 pumps, **S133–S136**
- insulin pump therapy, S128, S130, S131, **S133–S136**, S160, S162, S264, S270
- insulin resistance, S22, S23, S25, S27, S28, S30, S31, S47, S62, S65, S66, S67, S87, S97, S170, S172, S272, S284, S285, S286, S287, S288, S289, S298
- insulin secretagogues, S81, S88, S89, S120, S148, **S252**
- insulin therapy  
 access and affordability, S308  
 basal, S10, S119, **S129**, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, **S170**, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302  
 cost considerations, **S173**  
 dosing algorithms using machine learning, S126, S133, S135, S222, S246, S288, S296  
 in adults with type 1 diabetes, **S158–S164**  
 in adults with type 2 diabetes, **S164–S174**  
 combination injectable, **S174**  
 concentrated insulins, **S170**, S288, S299  
 in hospitalized patients, S298–S299  
 inhaled insulin, S8, S133, S158, S160, S173  
 in older adults, S250–S253  
 prandial, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300  
 insulin:carbohydrate ratio (ICR), S162
- integrated CGM devices, S130
- intensification  
 of obesity treatment, S8, S149  
 of diabetes therapy, S8, S160, S164, S168, S169, S174, S197 S141, S143, S149, S151, S154, S176
- intermittent fasting, S83
- intermittently scanned CGM devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269
- International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S34–S37
- islet transplantation, S161, **S164**
- isradipine, S237
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S9, S80, S221, S224
- ketoacidosis, diabetic, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**
- kidney disease. *see* chronic kidney disease.
- Kumamoto study, S116
- lactation, **S290–S291**
- language barriers, S16
- latent autoimmune diabetes in adults (LADA), S23
- Latino/Hispanic population, S15, S22, S27, S28, S79, S87



- LEADER trial, S198–S199, S204, S224
- lifestyle behavior changes, **S44–S46**
- delivery and dissemination of, **S45–S46**
  - Diabetes Prevention Program, **S44**
  - for diabetes prevention, **S44–S46**
  - for hypertension, **S184**
  - for lipid management, S186–S187
  - for weight management, S147–S148
  - in older adults, **S249**
  - in pediatric type 1 diabetes, S259, S266–S267
  - in pediatric type 2 diabetes, S259, **S268–S271**
  - in pregnancy, S286
  - nutrition, **S44–S45**
  - physical activity, **S45**
  - to reduce ASCVD risk factors, S180, S184
  - type 1 diabetes progression and, **S46**
- linagliptin, S172, S196, S202–S203, S206, S271
- lipase inhibitors, S151
- lipid management, S146, **S186–S187**, **S236**, S247, S254
- lipid profiles, S56, S186, S187, S259–S260, S266, S267
- liraglutide, S46, S68, S149, S151, S164, S169, S172, S173, S174, S198, S204–S205, S206, S224, S232
- lispro, S170, S172, S173, S250
- lixisenatide, S173, S174, S198, S204, S206
- long-acting insulin, S159, S169, S170, S252, S264, S269, S270
- Look AHEAD trial, S63, S69, S83, **S147**, S202, S249
- loss of protective sensation, S235, S237, **S238**
- lovastatin, S188
- machine learning, insulin dosing algorithms using, S296
- macular edema, diabetic, S232–S234, S252
- marijuana. *see* cannabis.
- maternal history, in screening children/adolescents, S27
- maturity-onset diabetes of the young (MODY), S23, **S32–S33**, S268
- meal planning, S80, **S82–S83**, S84, S284
- Medicaid expansion, S14
- medical devices, for weight loss, **S149**
- medical evaluation, S2, S3, S6, **S52–S76**, S146, S161, S187
- autoimmune diseases, **S59**
  - bone health, **S59**
  - cancer, **S62**
  - cognitive impairment/dementia, **S62**
  - comorbidities, **S59–S62**
  - comprehensive, **S54**, S55–S56
  - COVID-19, **S62–S64**
  - disability, **S64**
  - hepatitis C, **S64**
  - hyperglycemia, **S64**
  - hypoglycemia, **S64–S65**
  - immunizations, **S54–S59**
  - low testosterone in men, **S65**
  - nonalcoholic fatty liver disease, **S66–S68**
  - nonalcoholic steatohepatitis, **S66–S68**
  - obstructive sleep apnea, **S68–S69**
  - pancreatitis, **S69**
  - periodontal disease, **S69**
  - sensory impairment, **S69**
  - statins, **S69**
- medical nutrition therapy, S6, S45, S54, S57, S77, **S80–S88**, S113, S128, S154, S187, S259–S260, S261, S285
- alcohol, **S86**
- carbohydrates, **S84–S85**
- eating patterns and meal planning, **S82–S83**
- fats, **S85**
- food insecurity and access, **S82**
- goals of, **S80**
- in children and adolescents with type 1 diabetes, **S261**
- in hospitalized patients, **S301–S302**
- in pregnancy, **S287**
- micronutrient, and supplements, **S85–S86**
- nonnutritive sweeteners, **S86**
- protein, **S85**
- sodium, **S85**
- weight management, **S80–S82**
- Mediterranean diet, S6, S45, S68, S81, S82, S85, S186
- meglitinides, S9, S115, S117, S119, S148, S165, S172, S245, S249, S252
- mental health. *see* Psychosocial care.
- mental health referrals, S93, S95, S96
- mental illness, serious, **S97**
- metabolic surgery, S7, S8, S10, S58, S67, S68, S80, S93, S145, S146, S148, **S149**, **S153–S154**, S164, S168, **S271**
- metformin, S10, S46–S47, S56, S61–S62, S63, S68, S86, S116, S117, S148, S161, S165, S168, S169, S170, S172, S195, S196, S198, S200, S206, S210, S224, S225, S245, **S250–S252**, S260, S269, S270–S271, S272, S286, **S287–S288**, S290, S301,
- metoclopramide, S237
- metoprolol, S206, S237
- micronutrients, S80, S81, S83, **S85–S86**
- microvascular complications, S2, S7, S12, S28, S31, S33, S48, S55, **S90**, S96, S113, **S115–S116**, S117, S159, S164, S189, S181, S234, **S267–S268**, S270, S283,
- midodrine, S237
- miglitol, S172
- migrant farmworkers, S15–S16
- mineralocorticoid receptor antagonist therapy, S8, S185, S186, S220, S222, S223, S225, **S226–S227**
- monogenic diabetes syndromes, S22, **S32–S34**
- multiple daily injections (MDI), S55, S128, S129, S130, S131, S132, S133–S134, S135, S160, S162–S163, S270
- myasthenia gravis, S24, S59, S256
- naltrexone/bupropion ER, S150
- nateglinide, S46, S172, S252
- National Diabetes Data Group, S36
- National Diabetes Prevention Program, S45
- National Health and Nutrition Examination Survey (NHANES), S12, S35, S69, S268
- neonatal diabetes, S22, **S32**, S33, S258
- nephrologist, referral to, S220, S221, **S227**
- nephropathy, diabetic, S10, S28, S59, S60, S62, S97, S115, S164, S186, S196, S199, S201, S203, S224–S225, S231, S238, S259, S260, **S267**, S270, **S271**, S284
- neurocognitive function, **S245**
- neuropathic pain, S64, S235, **S236–S237**, S268
- neuropathy, diabetic, S9, S46, S54, S57, S59, S60, S64, S69, S86, S88, S97, S115, S116, S119, S120, S134, S169, S180, S202, **S234–S237**, S239, S259, **S267–S268**, **S272**, S284, S301
- auditory, S69
- autonomic, S59, S88, **S90**, S181, S234, S235, S301
- cardiac autonomic, **S235**
- gastrointestinal, **S235**
- genitourinary disturbances due to, **S235**
- peripheral, S46, S59, S64, **S78**, S86, **S90**, **S235**, S238
- new-onset diabetes after transplantation (NODAT), S31–S32
- niacin + statin therapy, **S192**
- nonalcoholic fatty liver disease (NAFLD), S55, S57, **S65–S68**, S284
- nonalcoholic steatohepatitis (NASH), S57, **S65–S68**, S167
- noninsulin treatments, S23, S25, S32, S68, S127, **S129**, S131, S132, **S161–S164**, S168, S169, S170, S172, S249, S250, S251, S269, S286, S295, S298, **S299**, S300, S302, S308
- noninsulin-dependent diabetes. *see* type 2 diabetes.
- nonnutritive sweeteners, S6, S81, S86
- NPH insulin, S159, S160, S163, S169, S170, S171, S172, S173, S174, S250, S252, S298, S300–S301
- nucleoside reverse transcriptase inhibitors, S32
- nursing homes, **S253–S254**
- nutrition, S6, S11, S13, S16, S22, S30, S35,
- for diabetes prevention/delay, **S44–S45**
- nutrition therapy. *see* medical nutrition therapy.
- obesity, S7–S8, S9, S10, S26, S27, S28, S30, S34, S44, S48, S55, S62, S65, S66, S67–S69, S80–S81, **S145–S157**
- assessment and monitoring, **S145–S147**
  - medical devices for weight loss, **S149**
  - metabolic surgery, **S149**, **S153–S154**
  - nutrition, physical activity, and behavioral therapy, **S147–S148**
  - pharmacotherapy, **S148–S149**, S150–S152
- obstructive sleep apnea, S55, S56, **S68–S69**, S97, S173, S186, S199, S260, **S272**
- ODYSSEY OUTCOMES trial, S189
- older adults, S9, S15, S57, S58, **S244–S257**
- bone health in, S59–S62
  - end-of-life care, S254
  - hypoglycemia, S245–S246
  - lifestyle management, S249
  - neurocognitive function, **S245**
  - pharmacologic therapy, S250–S253
  - in skilled nursing facilities and nursing homes, S253–S254
  - special considerations for, S253
  - treatment goals, S246–S249
  - with type 1 diabetes, S245, S246
- one-step strategy, for GDM, **S35–S36**
- opioid antagonist/antidepressant combination, S150
- opioids, S236, S237
- ophthalmologist, referral to, S90, S232, S233
- oral agents. *see also specific drugs.* **S129**, S253, S254, S288
- oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
- organ transplantation, posttransplantation
- diabetes mellitus, S23, **S31–S32**
- orlistat, S46, S150
- orthostatic hypotension, S182, S234, S235, **S237**
- overweight people, S9, S10, S27, S28, S30, S44, S45, S48, S67, S80, S81, S86, S87, S116, **S146–S147**, S148, S149, S180, S249, children and adolescents, S9–S10, S26, S27, **S268–270**,
- during pregnancy, S284, S288, S290
- oxygen, glucose monitors and, S129
- oxygen therapy, S240
- for advanced wound care, S240

- hyperbaric, S239, S240  
topical, S237, S239, S240–S241
- P2Y12 receptor antagonists, S193, **S195**  
palliative care, S248, S253, S254  
pancreas transplantation, S161, S164  
pancreatectomy, S31, S69, S135  
pancreatic diabetes, S6, **S30–S31**  
pancreatitis, S6, S23, S27, S30, S31, **S69**,  
S151–S152, S191, S205, S272  
paramedics, S14, S16, S45, S52, S79, S91, S169  
pens, insulin, S7, S126, S127, **S132–S133**  
periodontal disease, S30, **S69**  
perioperative care, S10, **S301**  
peripheral arterial disease, **S238–S239**  
peripheral neuropathy, S46, S59, S64, **S78**, S86,  
**S90**, **S235**, S238  
pernicious anemia, S24, S59  
person-centered care goals, S12, **S47–S48**, S12  
pharmacologic approaches. *see also* specific  
medications, medication classes.  
for adults with type 1 diabetes,  
**S158–S164**  
for adults with type 2 diabetes, **S164–S174**  
for cardiovascular and renal disease, S7  
**S202–S205**, S209–S210, S227  
for comorbidities, S57  
for hypertension, S184–S186  
for lipid management, S188–S192  
for neuropathic pain, S64, S235,  
**S236–S237**, S268  
for obesity, S7, **S148–S149**, **S150–S153**  
for pediatric type 2 diabetes, **S269–S271**  
for smoking cessation, S90  
in older adults, **S249–S253**  
in pregnancy, **S287–S288**, S289  
interfering substances for glucose meter  
readings, S129  
to delay or prevent type 2 diabetes, **S46–S47**  
to delay type 1 progression, **S48**  
to glycemic treatment, S8, **S158–S178**  
phentermine, S46, S149, S150, S152, S271  
phentermine/topiramate ER, S150  
phosphodiesterase type 5 inhibitors, S237  
photocoagulation surgery, **S233–S234**  
physical activity, S6, S10, S11, S28, S55, S57,  
S61, S64, S111, S127, S128, S135, S202  
exercise and youth, **S87**  
for diabetes prevention, S44, **S45–S46**  
frequency and type of, **S87**  
glycemic control and, **S88**  
high-intensity interval training, **S88**  
in children with type 1 diabetes, **S261–S262**  
in children with type 2 diabetes, S269  
in DSMES, **S86–S90**  
in obesity management, **S147–S148**  
in older adults, S249  
in pregnancy, **S287**  
with diabetic kidney disease, **S90**  
with microvascular complications, **S90**  
pre-exercise evaluation, **S88**  
pioglitazone, S47, S62, S67, S68, S172  
PIONEER-6 trial, S198–S199  
pitavastatin, S188  
plasma glucose test, 2-h, S20, **S21**, S23, S24, S26,  
S27, S30, S33, S35  
pneumococcal pneumonia vaccine, **S57**, S58  
point-of-care assays  
A1c, S21, S22, S112  
blood glucose monitoring, S136, S297  
polycystic ovary syndrome, S27, S28, S260, S272,  
S273, S284, S286, S287  
population health, S5, **S11–S19**  
access to care, S14  
behaviors and well-being, S13  
care teams, S13  
chronic care model, S12–S13  
cost considerations, S13–S14  
quality improvement, S14  
recommendations, S11  
tailoring treatment for social context,  
S14–S16  
status and demographics, S12  
telehealth, S13  
postbariatric hypoglycemia, S154  
postpartum care, in diabetic women, **S289–S291**  
posttransplantation diabetes mellitus, S23,  
**S31–S32**  
pramlintide, S161, S172, S237  
prandial insulin, S128, S160, **S170**, S171, S174,  
S250, S262, S270, S298, S300  
pravastatin, S188  
prediabetes, S5, S10, S21  
criteria defining, S22  
diagnosis, S27–S28  
lifestyle changes for prevention of diabetes,  
**S44–S46**  
prevention of vascular disease and mortality,  
**S47**  
screening in adults, S26, S27, S28–S30  
screening in children and adolescents, S30  
preeclampsia, in women with diabetes, S34,  
S35, S184, S282, S284, S285–S286, 288  
aspirin and, S289  
pregabalin, S148, S236  
pregnancy, S10, **S282–S294**  
A1C and, S22, **S285–S286**  
continuous glucose monitoring in, **S286**  
drug considerations in, **S89**  
gestational diabetes mellitus (GDM), S23,  
**S34–S37**, **S287–S288**  
glucose monitoring in, **S285**  
glycemic goals in, **S284–S286**  
insulin physiology in, **S288**  
lactation, **S290**  
lifestyle and behavior management, **S287**  
medical nutrition therapy, **S287**  
metformin in, **S287**  
pharmacologic therapy, **S287–S288**  
physical activity in, **S287**  
postpartum care, **S289–S291**  
pre-existing type 1 and 2 diabetes in,  
**S288–S289**  
preconception care, **S283–S284**  
preconception counseling, **S282–S283**  
preeclampsia and aspirin, **S289**  
real-time CGM device use in, **S131–S132**  
retinopathy during, **S232–S233**  
sulfonylureas, **S287**  
prevention, type 2 diabetes, S6, S7, S9, S14, S27,  
S28, **S43–S51**  
lifestyle behavior change for, **S44–S43**  
person-centered care goals, **S47–S48**  
pharmacologic interventions, **S46–S47**  
of vascular disease and mortality, **S47**  
proliferative diabetic retinopathy, S90, S233  
proprotein convertase subtilisin/kexin type 9  
(PCSK9) inhibitors, S8, S30, S187, S188, **S189**,  
**S190**, S192  
protease inhibitors, A1C and, S30  
protein intake, S9, S10, **S85**, S158, S220, S223,  
S249, S270, S271  
psychosocial care, S6, S9, S77, **S91–S98**  
anxiety disorders, **S94**  
assessment and treatment, **S92–S93**  
cognitive capacity/impairment, **S96–S97**  
depression, **S95**  
diabetes distress, **S93–S94**  
disordered eating behavior, **S95–S96**  
in pediatric type 1 diabetes, S261,  
**S262–S263**  
in pediatric type 2 diabetes, S273  
referral to mental health specialist, S93,  
S95, S96  
screening, S92  
serious mental illness, **S96**  
sleep health, S97  
pumps, insulin, **S133–S136**  
do-it-yourself closed-loop system, S135, S159  
in youth, S7, S134, S263, S270  
sensor augmented, S134  
quality improvement, S5, **S14**, S295, S299  
RAAS inhibitors, S163  
race, S22, S27, S63, S64, S79, S112, S148, S196,  
S198, S200, S221  
rapid-acting insulin analog, S134, S135, S159,  
S160, S163, S170, S173, S250, S254, S262,  
S285, S298, S299, S301, S302  
real-time CGM devices, S7, S94, S121, S129,  
S130, S263, S254, S269, S284, S286, S297  
REDUCE-IT trial, S85, S191  
referrals, S6, S14, S16, S66, S78  
for behavioral health professionals, S92  
for community screening, S30  
for comprehensive eye exam, S57, S267  
for food insecurity, S82  
for initial care management, S57  
for local community resources, S16  
for DSME, S54, S57, S78, S79  
for tobacco cessation, S54  
from dentist to primary care, S57  
to behavioral health provider, S92, S93  
to foot care specialist, S239  
to gastroenterologist, S65, S69  
to mental health professional, S93, S95, S96  
to nephrologist, S220, S221, **S227**  
to neurologist, S235  
to sleep specialist, S98, S260  
to registered dietitian nutritionist, S45,  
S57, S149, S261, S265, S283, S302  
registered dietitian nutritionist (RDN), S45, S57,  
S80, S82, S282, S285, S287, S288 43, S255,  
S257, S274  
reimbursement, S14, S45  
for CGM in adults with type 2 diabetes, S9  
for DSMES, S6, S78, **S79**  
religious fasting, **S83**  
repaglinide, S172, S252  
resistance training, S45, S68, S88, S249  
respiratory syncytial virus (RSV) vaccine, S57–S58  
retinopathy, diabetic, S66, S90, S115, S227,  
**S231–S234**, S267, S272, S283  
screening, S232–S233  
treatment, S233–S234  
visual rehabilitation, S234  
REWIND trial, S198–S199, S204  
risk calculator, for ASCVD, **S180**  
risk management  
cardiovascular disease, S8, **S179–S218**  
chronic kidney disease, S9, **S219–S230**  
risk, screening for  
type 1 diabetes, S26  
prediabetes and type 2, S27, S29  
rivaroxaban, S193, S194

- rosiglitazone, S148  
Roux-en-Y gastric bypass, S153
- SAVOR-TIMI trial, S196, S206  
saxagliptin, S172, S196, S206, S299  
schizophrenia, S96  
schools, diabetes care in, **S127**, S261, **S262**, S263, S268, S308  
screening, S5, S6, S7, S9  
    after acute pancreatitis, S31  
    by age, S30,  
    community, S30  
    for cystic fibrosis-related diabetes, S31  
    for gestational diabetes mellitus, S34, S36  
    for neuropathy, S235–S236  
    for prediabetes and type 2 diabetes, S26–S30  
    for type 1 diabetes, S26  
    for type 2 diabetes, S27 **S240**  
    in children/adolescents, S30  
    in dental practices, S30, S55, S57  
    in people with HIV, S30  
    medications, S30  
    testing interval, S30  
    use of A1C for, S21–S22  
    use of FPG or 2-h PG for, S21  
seasonal farmworkers, S15–S16  
self-monitoring of blood glucose (SMBG). *see*  
    blood glucose monitoring (BGM)  
semaglutide, S8, S46, S68, S148, S149, S150, S165, S168, S169, S172, S198–S199, S204, S205, S206, S224–S225, S226, S232, S252  
sensor-augmented pumps, S134  
sensory impairment, S69  
setmelanotide, S149  
sexual dysfunction, S235  
sickle cell disease, A1C and, S22, S112, S284  
simvastatin, S188, S189, S192  
sitagliptin, S169, S172, S196, S206  
skilled nursing facilities, S251, **S253–S254**  
sleep health, S7, **S97–S98**  
smart pens. *see* connected insulin pens  
smoking cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
social capital, S5, S14, **S15**  
social context, S14–S16  
social determinants of health (SDOH), S12, S13, S14–S15, S16, S79, S92, S166  
sodium channel blockers, S235, **S236**  
sodium intake, S81, S84, **S85**, S184, S223  
sodium-glucose cotransporter 2 (SGLT2) inhibitors, S8, S28, S62, S68, S84, S116, S148, S164, S166, S167, S172, S180, S195, S201, S209, S220, S222, S225, S246, S250, **S252**, S270, S299  
SOLOIST-WHF trial, S208  
sotagliflozin, S206, S207, **S208**  
SPRINT trial, S181, S182, S183, S205  
staging  
    of diabetic kidney disease, S57, **S221–S222**  
    of type 1 diabetes, S24  
statin therapy, S8, S9, S47, S67–S68, S116, S180, S187, **S187–S192**,  
    combination therapy with, S190–S191  
    diabetes risk with, **S192**  
    high- and moderate intensity, S188  
    intolerance to, S190  
    primary prevention, **S187**, **S188**  
    secondary prevention, **S188–S189**  
    with bempedoic acid, S8, S187, **S191**  
    with ezetimibe, S189  
    with fibrate, S169, **S170**, **S192**  
    with niacin, S169, **S170**  
    with PCSK9 inhibitors, S189–S190  
statins, S26, S30, **S57**, **S69**, S85, S192, S197, S198, S202  
stem cell therapies, for wounds, S240  
strength training, S44, S269  
sulfonylureas, S9, S15, S32, S33, S62, S68, S113, S115, S116, S117, S119, S120, S148, S165, S168, S172, S174, S245, S249, S250, S252, **S287**  
supplements, dietary, S61, S81, **S85–S86**, S141, S148, S154, S283, S284  
surveillance  
    behavioral risk factor surveillance system, S79, S94  
    BGM system, S128  
    for foot problems, S237, S238–S239  
    of chronic kidney disease, **S222–S223**  
    of NAFLD patients, S66  
SUSTAIN-6 trial, S198–S199, S204, S224  
sweeteners, nonnutritive, S6, S81, S86  
sympathomimetic amine anorectics, S150  
    in combination with antiepileptic, S150  
syringes, insulin, **S132–S133**
- tapentadol, **S236**  
technology, diabetes, S7, S8, S13, **S126–S144**  
    blood glucose monitoring, **S127–S129**  
    continuous glucose monitoring devices, **S129–S132**  
    general device principles, **S126–S127**  
    insulin delivery, **S132–S137**  
technology-assisted prevention programs, S44, S45–S46, S79, S94  
TECOS trial, S196, S206  
TEDDY study, S26, S46  
telehealth, S6, **S13**, S15, S45, S78–S80, S286  
temperature  
    of glucose monitor, S129  
    perception of, S56, S234, S235, S237, S238  
teplizumab, S48  
testing interval, S30  
testosterone  
    in diabetes prevention, S46  
    low, in men, **S65**  
tetanus, diphtheria, pertussis (TDAP) vaccine, S58, S284  
thiazide-like diuretics, S185, S186, S224  
thiazolidinediones, S46, S59, S60, S148, S165, S206, S245, **S252**  
thyroid disease  
    autoimmune, S33, S59, S266  
    in pediatric type 1 diabetes, S259, **S265**  
time-restricted eating, S83  
tirzepatide, S46, S62, S68, S148, S149, S152, S165, S168, S169, S172, S252  
tobacco use/cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
training  
    blood glucose awareness, S121  
    health professionals/staff, S10, S13, S16, S79  
    high-intensity interval, S6, **S88**  
    on device use, S10  
    resistance, S6, S44, S45, S68, S79, S88  
    self-care, S16  
    strength, S44, S269  
tramadol, **S236**  
transfusion, A1C and, S22, S112, S247  
transition  
    from hospital to ambulatory setting, S295, **S302–S303**  
    from IV to SC insulin, **S298–S299**  
    from pediatric to adult care, S258, **S273–S274**  
transplantation  
    islet, S161, **S164**  
    liver, S65, S66  
    organ, post-transplant diabetes mellitus after, S23, **S31–S32**  
    pancreas, S161, **S164**  
    renal, S161, S164, S196, S201, S207, S208, S221, S225  
tricyclic antidepressants, S148, S235, **S236**  
TWILIGHT trial, S194  
two-hour plasma glucose (2-h PG) test, S20, **S21**, S23, S24, S26, S27, S30, S33, S35  
two-step strategy, for GDM, **S36**  
type 1 diabetes, S5, S6, S7, S8, S9, S10, S13, S14  
    beta-cell replacement therapy, S161, S164  
    in children/adolescents, **S233–S240**  
    classification, S22–S23  
    diagnosis, **S24–S26**  
    idiopathic, S27  
    immune-mediated, **S24**, **S26**  
    in hospitalized patients, S296, **S298**, S300  
    lifestyle and progression of, S46  
    insulin therapy, S158, **S159–S160**  
    noninsulin treatments, **S161**, **S164**  
    in older adults, S245, S246  
    peripheral neuropathy in, S234–S236  
    pregnancy in women with preexisting, S283, S284, S285, S286, **S288**, S290  
    retinopathy in, S232  
    screening, S26  
    staging, S24  
    subcutaneous insulin regimens, S159–S161, S163–S164  
    surgical treatment, **S164**  
    teplizumab to delay symptoms, S48  
type 2 diabetes, S5, S6, S7, S8, S9, S10, S12, S13, S15, S22–S23  
    in children/adolescents, **S268–S273**  
    classification, **S20–S22**  
    combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252  
    diagnosis, **S26–S31**  
    insulin pump use in, S135  
    obesity and weight management, S29, S67, **S145–S157**, S165, S168  
    pharmacologic treatment in adults, **S164–S174**  
    pregnancy in women with preexisting, **S288–S289**  
    prevention or delay, S6, S7, S9, S14, S27, S28, **S43–S51**  
    retinopathy in, S233  
    risk test for, S29  
    screening in asymptomatic adults, S27, S28, S29  
    screening in children/adolescents, S28, S30  
    surgical treatment for, S164  
type 3c diabetes, S30  
UK Prospective Diabetes Study (UKPDS), S116, S117, S197, S205  
ulcers, foot, S9, S56, S88, S90, S234, **S237–S241**  
ultra-rapid-acting insulin analogs, S159, S160, S163  
ultrasound wound debridement, S240  
vaccines. *see* immunizations  
vagus nerve stimulator, S149  
vascular disease, S90, S116, S117, S181, S183, S192, S194, S202, S237  
    prevention of, in prediabetes, **S47**  
VERIFY trial, S168

- vertical sleeve gastrectomy, S153  
 VERTIS CV trial, S200, S201, S204  
 Veterans Affairs Diabetes Trial (VADT), S64, S116, S246  
 vildagliptin, S168  
 vitamin D supplementation, S46, S56, S60, S61, S81, S85–S86, S148  
 VOYAGER-PAD trial, S194
- weight loss surgery. *see* metabolic surgery.  
 weight loss/management, S7, S8, S31, S31, **S80–S82**, S83, S86, S87, S93, S96, S117, S136, **S145–S154**, S184, S186, S202, S236,  
   in diabetes prevention, S44–S46, S47, S48  
   in children/adolescents, S269, S271, S272  
   in older adults, S249, S251, S252  
   in pregnancy, S290  
   in type 1 diabetes, S46, S61, S161  
   in type 2 diabetes, S29, S67, S165, S168  
   medical devices for, **S150**  
   metabolic surgery for, **S149, S153–S154**  
   pharmacotherapy for, **S148–S149**, S150–S152  
   with NAFLD, S67–S68
- unexpected, S21, S23, S20, S24, S28, S62, S95, S253  
 well-being, S6, **S13**, S35, S53, S65, **S77–S110**, S146, S234, S263  
 whites, non-Hispanic, S22, S25, S27, S60, S63, S112, S196, S198, S200,  
 WISDM trial, S246  
 Wound therapy, advanced, S239–S241
- Youth. *see* Children and adolescents.
- zoster vaccine, S59